重组人血管内皮抑素联合化疗心脏毒性的分析

目的: 评价重组人血管内皮抑素联合化疗的心脏不良反应。 方法: 收集12例应用重组人血管内皮抑素联合化疗恶性肿瘤患者的临床资料,观察治疗过程中患者有无心慌、胸闷、呼吸困难等临床症状,心电图,心肌酶谱及左心室射血分数(LVEF)的改变,筛选心脏毒性的早期诊断的指标。 结果: 治疗1周和治疗结束时与治疗前相比CK-MB升高具有显著性意义(P<0.05),治疗结束时与治疗前相比心电图改变有显著性意义(P<0.05)。治疗后与治疗前LVEF值的改变无显著性意义。 结论: 初步认为重组人血管内皮抑素联合化疗存在轻度的心脏不良反应,对心肌有一定的损伤,但是心功能未受到明显改变。CK-MB和心电图可作为早期监测心脏毒性的检查指标。在重组人血管内皮抑素联合化疗的过程中应该警惕心脏不良反应的发生。

Analysis of Cardiotoxicity of Recombinant Human Endostatin Combined with Chemotherapy

Objective: To evaluate the cardiotoxicity of recombinant human endostatin combined with chemotherapy. Methods: A total of 12 patients with cancer who had been treated with recombinant human endostatin combined with chemotherapy were selected and their clinical data were collected. During the treatment, the changes in electrocardiogram (ECG), myocardium enzymogram and left ventricular ejection fraction(LVEF) were monitored. Results: After therapy, CKMB was higher in the middle period to the end of treatment, with a significant difference (P<0.05). ECG changed significantly at the end of treatment compared with its appearance before therapy (P<0.05), while LVEF had no significant changes (P>0.05). Conclusion: Recombinant human endostatin combined with chemotherapy has mild adverse cardiac effects and causes negligible myocardial injury, but it rarely changes cardiac function. CK-MB and ECG can be used as indices for early detection of endostatin-induced cardiotoxicity and should be given more attention during treatment with recombinant human endostatin combined with chemotherapy.